by Daniel X. Thomas
EP 2 548 648 B1 relates to a mill for comminating of material.
The material to be comminated “essentially” enters radially (11) and the material is also discharged radially after having travelled along the drum, whereby the discharge opening (13) opening is free of sieves.
Procedure before the EPO
The patent was directly granted by the EPO on the basis of an ESR only mentioning 2 A,D and 1 A document.
by Daniel X. Thomas
EP 3 756 153 A1 has been published as WO 2019/164758, and relates to a pump chemical compatibility management system.
To prevent damage to the pump, an operator scans an RFID tag attached to a reservoir containing the chemical and an RFID tag attached to the selected pump.
by Daniel X. Thomas
EP 4 185 356 B1 relates to a nasal canula.
The patent was not opposed at the EPO.
Brief outline of the case before the UPC
Fisher & Paykel Healthcare Limited lodged a revocation action against Flexicare (Group) Limited before the CD-CFI Milan.
by Daniel X. Thomas
The present blog entry is rather long. This is however necessary, since a decision of a TBA-EPO is compared with a decision of a UPC-CFI LD Munich.
EP 2 493 466 B1 relates to a novel antitumoral use of cabazitaxel in the treatment of prostate cancer and has been claimed under Art 54(5) EPC.
by Daniel X. Thomas
Brief outline of the cases of the EPO
EP 3 666 797 B1 relates to antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.
The opposition filed by compagnies of the Sanofi group and Regeneron has been rejected by the OD.